On World Malaria Day 2021, EDCTP joins all partners in the ‘Zero Malaria – Draw the Line Against Malaria’ campaign towards the goal of malaria elimination. Towards malaria research & development, EDCTP has invested more than €150 million to support a portfolio of 64 research projects conducted by African-European consortia and research fellows in Africa.
These projects support the development of innovative products – diagnostics, drugs and vaccines – needed to manage, control and eliminate malaria. EDCTP funding progressed the development of the R21 vaccine that recently demonstrated greater than 75% protection in a recent phase II trial. The EDCTP malaria portfolio also includes studies on implementation of interventions and activities to strengthen health systems, essential to ensure successful roll-out of new and existing products, and to contribute to the malaria eradication agenda.
“We must not waver in our efforts to control and steadily move towards malaria eradication, despite the COVID-19 pandemic and other challenges. The recent exciting results from the clinical development of the R21 malaria vaccine in Burkina Faso bring us a step closer to a highly effective malaria vaccine. We remain committed to support the development of new and improved products for the diagnosis, prevention and treatment, as well as product-focused implementation research to ensure that these products reach the populations that need them most.”
Dr Michael Makanga, EDCTP Executive Director
For more about EDCTP funded malaria projects visit https://www.edctp.org/news/world-malaria-day-2021/
Read moreSafety, Efficacy, Uptake and Equitable Access
Multiple COVID-19 vaccines are now approved for use and a global vaccination effort is underway.
To receive an update on the latest vaccine developments and the implementation of vaccination strategies, join the second edition of our virtual series on COVID-19 vaccines with topics to include vaccine efficacy and safety concerning real-world data. World experts will discuss new diagnostic tools to detect emergent SARS-CoV-2 variants and measure protection against infection and its durability.
Interactive lectures will dive into the prospects of vaccine development, including novel vaccine targets, and tackling vaccine hesitance in vulnerable populations, among other burning questions.
For more information visit https://virology.eventsair.com/covid-19-vaccineworkshop/registration/Site/Register
We are pleased to announce that the International Workshop on HIV Pediatrics 2021 will offer virtual scholarships to help offset the cost of registration and/or internet connection for delegates who would otherwise be unable to attend. Applications will be reviewed by a dedicated review committee.
Available scholarships include:
• Registration only
• Data bundle only
• Registration & data bundle
To be eligible applicants must:
• Be actively involved in the field of HIV Pediatrics
• Be able to show benefits to their patients / research / community from attending the workshop
• Be willing and able to share information learned at the workshop with a larger community
Apply for your scholarship now and join HIV Pediatrics 2021! Scholarship Application Deadline: 30 April 2021 at 23:59 CEST https://virology.eventsair.com/hiv-pediatrics-2021/scholarships/Site/Register
We are pleased to inform you that abstract submission is open for the Microbiome & HIV Workshop 2021. Researchers are invited to present their latest studies or share their experiences in the microbiome and HIV field until 5 September 2021.
Abstracts can be submitted under the following categories:
• Comorbidities
• Microbicides / Vaccines
• Pathogenesis
• Technologies & Methodologies
• Transmission & Prevention
• Treatment & Cure
Young Investigators and Academia from Resource-Limited Settings with accepted abstracts will be provided with a registration waiver fee to join the workshop.
Visit our website for further information on abstract submission and available discounts for submitters - https://academicmedicaleducation.com/microbiome-hiv-2021